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“We are witnessing a revolution in the treatment of
hepatitis C virus…. There is no question that these
treatments that can save millions of lives must be
made universally available at an affordable price.” –
Francois Barre-Sinoussi, President of the International
AIDS Society [1]
Globally, approximately 184 million people are chroni-
cally infected with the Hepatitis C virus (HCV), the major-
ity of whom reside in low- and middle-income countries
[2]. HCV is a very common co-infection of HIV with an
estimated four to five million people affected [3]. While
HCV is a global epidemic it has a disproportionate effect
on marginalised groups, in particular people who inject
drugs (PWID). The global prevalence of HCV among
PWID was estimated at 67% in 2010, with more than
10 million PWID living with the virus [4]. Moreover,
among PWID who are living with HIV, approximately
75% are co-infected with HCV [5]. While the burden of
HCV falls disproportionately upon people who inject
drugs, treatment coverage among this group remains
extremely low, estimated at just 2%-4% of those eligible
for treatment [6]. This is similar to the 4% coverage of
antiretroviral therapy among PWID who are living with
HIV [7].
A treatment revolution?
While both HIV and Hepatitis C are bloodborne viruses,
Hepatitis C is curable. Until recently, the standard of care
was pegylated interferon (PEG-IFN) and ribavirin (RBV),
but this regimen has significant drawbacks, including the
requirement of a long treatment duration (24 to 48 weeks
or longer) and frequent and sometimes severe side effects
from both drugs [8]. Moreover, cure rates are low, at
around 50% in low- and middle-income countries [9].
Recent developments in direct-acting antivirals (DAAs) to
treat HCV have been hailed as revolutionary [10], and
adding a first-generation DAA to PEG-IFN/RBV increased
cure rates in genotype 1 patients to 75% [11]. (Genotype 1
is the most prevalent HCV genotype globally, and tradi-
tionally the most difficult to cure.) Newer-generation
DAAs have brought cure rates up to 90% or higher and
are easier to take [12]. Within the next couple of years, it
is expected that all-oral DAA combinations with few side
effects, taken for 8 to 12 weeks, will cure most people with
HCV including those considered “hard to treat [13].”
Many pharmaceutical companies are producing HCV
DAAs and there are dozens of additional treatment candi-
dates in the drug development pipeline. Several products,
including Gilead’s sofosbuvir and Janssen’s simeprevir,
have recently been approved in the United States and
Europe [14].
Profits before patients?
A substantial body of literature suggests that HCV is
treatable among PWID and that, with the right support,
adherence levels among PWID are equal to those of their
non-drug-using peers [15]. Many of the barriers that
exclude this group from treatment are structural or are
based on stigma and discrimination [6]. However another
significant barrier for all people with HCV, particularly in
relation to new medications, is cost. Eighty-five percent of
Hepatitis C patients reside in low- and middle-income
countries, many of which have meagre health budgets, and
patients in these countries generally are expected to pay
for medications out-of-pocket [16]. Pegylated interferon,
at around US$ 20,000 per course of treatment, has proven
to be too expensive for people in many countries [16].
Sofosbuvir, which is expected to be the mainstay of HCV
therapy for the near future, has the potential to benefit
many more patients when combined with other medica-
tions, but its cost of US$ 84,000 per 12-week course (with
comparable prices in Europe) will keep it out of reach for
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the majority of hepatitis C patients for the foreseeable
future [16,17].
Given that the market for sofosbuvir will have an esti-
mated worth of around US$ 9 billion by 2017 [18], civil
society organisations and treatment advocates have called
for a reduction in the price of new medications to
US$ 500 per course [19].
Some progress has already been made through advocacy:
in Egypt, which has the highest HCV prevalence in the
world at 14% in the general population [20], the produc-
tion of generic medications to rival brand-name competi-
tors has allowed the government to secure prices of just
US$ 2,000 per course of PEG-IFN [16]. Most recently the
government negotiated a 99% discount on the US price of
sofosbuvir, bringing it down to just US $900 per 12-week
course [21].
Moreover, India ’s Natco Pharma Limited has
requested that the Indian patent office deny Gilead a
patent for sofosbuvir in India, arguing that the new
medication is not “innovative enough” and relies upon
“old science.” If this request is approved, it will pave
the way for the generic production of the drug [22].
Most recently, the World Health Organization issued
a strong statement within new guidelines for hepatitis
C treatment recommending the use of new medica-
tions, including sofosbuvir, and urging a reduction in
price [23].
What does this mean for Europe?
While the introduction of these new drugs constitutes
one of the most important medical breakthroughs in
recent years, the exorbitant cost means that even within
Europe they are unlikely to be made available to PWID.
In most Eurozone countries, sofosbuvir will be priced at
EUR 50,000 to 60,000 per 12-week course [24].
A treatment gap is already evident for less costly hepati-
tis C treatment within the European Union: large varia-
tions have been reported between the economically stable
countries in northern and western Europe and those
greatly affected by the 2009 financial crisis in southern
and eastern Europe. It was estimated that 6.7% of hepatitis
C patients in France undertook treatment in 2010, com-
pared to just 0.8% in Italy [25]. The treatment rate was
also very low in Poland (0.4%), Romania (1.0%) and Russia
(0.3%), and it has been suggested that the cost of treat-
ment was a factor [25].
Even in high-income countries, the cost of new treat-
ment is likely to have an impact on uptake. For example,
in France it has been estimated that the price charged by
Gilead is 756 times the cost of production of sofosbuvir
[17]. With 127,500 chronic HCV patients [17] within
France who could benefit from sofosbuvir, the high cost
virtually guarantees that this is not a sustainable treatment
option.
Twenty-one countries within Central Asia and Eastern
Europe are currently classified as having middle-income
status [26]. These countries, which are excluded from
licensing agreements with Gilead, have small health bud-
gets and will be unable to purchase these treatments [24].
Due to the withdrawal of the Global Fund to Fight
AIDS, Tuberculosis and Malaria and other international
donors, harm reduction programmes are under threat in
countries such as Bulgaria, Georgia and Moldova [27]. Not
only did Global Fund support ensure the continuation of
harm reduction services in the past, but it also was a factor
in the negotiation of lower hepatitis C medication prices in
countries such as Ukraine [28].
Recommendations
Gilead should drastically reduce the price of sofosbuvir.
Doing so will promote access to this lifesaving treatment.
It has also been suggested that sales would increase and
profits would stabilise [24]. Gilead should also commit to
an early access programme for European countries whose
healthcare systems are unable to afford sofosbuvir [24].
Generic competition must be fostered; the recent devel-
opments in India are paving the way for this dynamic to
emerge. The success seen in price reductions for HIV
medications as a result of the introduction of generic
products should provide a model upon which HCV treat-
ment advocates can expand.
Within those countries in the European region that are
still eligible for Global Fund support, the Global Fund
should increase its attention to hepatitis C. While the
Global Fund does not have a specific strategy for increas-
ing access to hepatitis C prevention, treatment and care, it
does have supportive guidance. In countries with “well-
documented evidence that hepatitis C treatment and fund-
ing is available to the general population,” Global Fund
monies can be used to “fill in the gap for HIV-infected
individuals [29].” The Technical Review Panel has recom-
mended that Global Fund resources be used to amass
evidence on the need for hepatitis treatment, create aware-
ness of the virus, increase prevention efforts, and support
advocacy for treatment access and affordability [30]. The
Global Fund could draw on the experience accumulated in
programmes focusing on HIV/HCV co-infection, such as
in Georgia and Ukraine, where negotiations regarding
the cost of medications have led to substantial price
reductions.
European civil society should learn from how reduc-
tions in the prices of HIV medications have been
achieved and should apply similar pressure in relation to
hepatitis C medications. A coordinated effort from a vari-
ety of stakeholders in Europe should be undertaken. Pro-
mising developments such as those seen mostly recently
in Egypt and India around generic production should be
encouraged and extended.
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Civil society should be closely involved in HCV policy
and programme development. In particular, the meaning-
ful engagement of people who use drugs is key. Funding
should also be directed towards these groups as a priority.
Innovative advocacy and coordinated efforts by civil
society have resulted the formation of an HCV civil society
reference group at the World Health Organization and the
inclusion of PEG-IFN on the list of essential medicines
[31]. These strategies should be leveraged within Europe
to ensure that PWID there can also access new and emer-
ging treatments.
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